Loading
A phase 1/2 trial of LCB84 in advanced solid tumours, run by LigaChem Biosciences, Inc., now recruiting.
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05941507 by LigaChem Biosciences, Inc., with 300 participants planned, started 2023-10-05 and due to reach its primary completion in 2027-01. Interventions recorded: LCB84 and Anti-PD-1 monoclonal antibody.
Shares LigaChem Biosciences, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LigaChem Biosciences and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.